Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Change in Accured Expenses (2016 - 2025)

Wave Life Sciences (WVE) has disclosed Change in Accured Expenses for 11 consecutive years, with $10.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses rose 45.22% year-over-year to $10.1 million, compared with a TTM value of $5.5 million through Dec 2025, up 28.92%, and an annual FY2025 reading of $5.5 million, up 28.92% over the prior year.
  • Change in Accured Expenses was $10.1 million for Q4 2025 at Wave Life Sciences, up from $3.5 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $10.1 million in Q4 2025 and bottomed at -$13.3 million in Q1 2025.
  • Average Change in Accured Expenses over 5 years is $729650.0, with a median of $3.4 million recorded in 2021.
  • The sharpest move saw Change in Accured Expenses crashed 102.01% in 2022, then surged 7668.97% in 2023.
  • Year by year, Change in Accured Expenses stood at $3.5 million in 2021, then soared by 85.76% to $6.5 million in 2022, then plummeted by 35.28% to $4.2 million in 2023, then soared by 65.06% to $6.9 million in 2024, then skyrocketed by 45.22% to $10.1 million in 2025.
  • Business Quant data shows Change in Accured Expenses for WVE at $10.1 million in Q4 2025, $3.5 million in Q3 2025, and $5.2 million in Q2 2025.